A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Zongertinib in the Blood

NCT06028464 PHASE1 COMPLETED Results posted

The main objective of this trial is to investigate the effect of multiple oral doses of the strong CYP3A inducer carbamazepine on the pharmacokinetics of a single dose of BI 1810631 in plasma.

Details

Lead sponsor	Boehringer Ingelheim
Phase	PHASE1
Status	COMPLETED
Enrolment	16
Start date	Mon Sep 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Healthy

Interventions

• Zongertinib
• Carbamazepine

Countries

Germany